| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| filingDate |
2000-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2002-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2002538170-A |
| titleOfInvention |
Anti-TNFα antibodies in the treatment of asthma |
| abstract |
(57) [Summary]nThe present invention relates to the use of an anti-TNFα antibody or an antigen-binding fragment thereof for the manufacture of a medicament for use in treating asthma or airway inflammation in the treatment of an individual in need thereof. provide. The invention also provides an anti-TNFα antibody or antigen thereof for producing a medicament for use in reducing the accumulation of inflammatory cells in the lung in an individual in need thereof. The use of a binding fragment is provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010533181-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014508930-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006517214-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014062095-A |
| priorityDate |
1999-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |